Review
doi: 10.1016/b978-0-7506-9265-6.50008-7.
Recent advances in the development of pertussis vaccines
- PMID: 1600382
- DOI: 10.1016/b978-0-7506-9265-6.50008-7
Item in Clipboard
Review
Recent advances in the development of pertussis vaccines
Biotechnology.
1992.
No abstract available
Similar articles
-
Role of pertactin in pertussis vaccines: the jury is still out.J Infect Dis. 2004 Apr 1;189(7):1332-3; author reply 1333-5. doi: 10.1086/382158. J Infect Dis. 2004. PMID: 15031804 No abstract available.
-
Evolution of whooping cough bacterium may reduce vaccine effectiveness.Hum Vaccin Immunother. 2014;10(6):1430. Hum Vaccin Immunother. 2014. PMID: 25396233 No abstract available.
-
Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.Expert Rev Vaccines. 2014 Sep;13(9):1135-46. doi: 10.1586/14760584.2014.932254. Epub 2014 Jun 23. Expert Rev Vaccines. 2014. PMID: 24953157 Review.
-
Molecular aspects of Bordetella pertussis pathogenesis.Int Microbiol. 1999 Sep;2(3):137-44. Int Microbiol. 1999. PMID: 10943406 Review.
-
Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.Pediatrics. 2001 Dec;108(6):E115. doi: 10.1542/peds.108.6.e115. Pediatrics. 2001. PMID: 11731642 Review.
Cited by
-
VopX, a novel Vibrio cholerae T3SS effector, modulates host actin dynamics.mBio. 2025 Mar 12;16(3):e0301824. doi: 10.1128/mbio.03018-24. Epub 2025 Jan 29. mBio. 2025. PMID: 39878476 Free PMC article.
-
Antigenic analysis of Bordetella pertussis filamentous hemagglutinin with phage display libraries and rabbit anti-filamentous hemagglutinin polyclonal antibodies.Infect Immun. 1998 Oct;66(10):4884-94. doi: 10.1128/IAI.66.10.4884-4894.1998. Infect Immun. 1998. PMID: 9746593 Free PMC article.